Sarepta Therapeutics (SRPT) Tops Q3 EPS by 68c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $467.2 million versus the consensus estimate of $407.73 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• U.S. judge won't block Trump's UFC mixed martial arts event at White House on June 14
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO